Galux and LG Chem Initiate Joint Research on AI-Powered Cancer Drug Development
 

• LG Chem invests in Galux, which has developed a world-class antibody design AI platform, “GaluxDesign”

• Collaboration expected to accelerate the discovery of novel anticancer protein therapeutics through cutting-edge AI technology

Galux announced that it has entered into a joint research agreement with LG Chem to develop novel anticancer protein therapeutics using Galux’s proprietary AI drug design technology.

Under the agreement, Galux will leverage its AI platform to design lead candidates that overcome the limitations of conventional cancer treatments, while LG Chem will be responsible for optimizing the lead compounds, conducting preclinical studies, and driving global clinical development. LG Chem anticipates that Galux’s platform will enable faster development timelines and yield novel, differentiated drug candidates for new targets.

Galux previously unveiled its next-generation antibody design AI, GaluxDesign, a platform demonstrating performance on par with leading global technologies such as AlphaFold by Google DeepMind and RosettaFold by the University of Washington. According to data published on bioRxiv, GaluxDesign outperforms existing AI antibody design tools, showing more than fivefold improvement in benchmark tests over technology disclosed by U.S.-listed biotech company Absci. The company’s technological excellence attracted investment from LG Chem last year.

Professor Min-Kyung Baek, a key contributor to the development of RosettaFold and now a faculty member at Seoul National University, commented “Korea’s AI drug design capabilities have reached global standards. Galux’s antibody design technology is among the most advanced in the world. I hope this collaboration with LG Chem will serve as a milestone in establishing Korea’s leadership in AI-driven drug discovery.”

Mr. Hee-Bong Lee, Executive Vice President and Head of R&D at LG Chem Life Sciences, stated “By partnering with Galux, a leader in protein design AI, we aim to accelerate the development of globally competitive cancer therapeutics.”

Founded in 2020 by Professor Chaok Seok of Seoul National University’s Department of Chemistry and three researchers (Tae-Yong Park, Jong-Hoon Won, and Jin-Sol Yang), Galux has raised over USD 18 million to date. The company’s proprietary platform is built on the physical principles underlying molecular behavior, offering a transformative approach to drug discovery. Galux aims not only to dramatically reduce the cost and timeline of drug development, but also to create breakthrough therapies for intractable diseases.